Table 3.
Analysis of the results of studies listed in Table 2.
| Publication | Patient population | Endpoints/definition of CIN | Contrast media | Results |
|---|---|---|---|---|
| Aspelin et al. [17] | Patients with CRI and diabetes | SCr ≥0.5 mg/dL 72 h after administration | Iodixanol 320 (N=64) Iohexol 350 (N=65) |
Iohexol >Iodixanol (26% vs. 3%, p < 0.05) |
| Briguori et al. [18] | Patients with CRI | SCr ≥0.5 mg/dL 48 h after administration | Iodixanol 320 (N=110) Iobitridol 350* (N=115) |
No significant difference (Iodixanol 3%, Iobitridol 4%, p=n.s.) |
| Jo et al. [19] | Patients with CRI | SCr ≥0.5 mg/dL and/or SCr ≥25% 1–2 days after administration | Iodixanol 320 (N=140) Ioxaglate 320 (N=135) |
Ioxaglate > Iodixanol (17% vs. 8%, p<0.05) |
| Rudnick et al. [20] | Patients with CRI | SCr ≥0.5 mg/dL 24, 48 and 72 h after administration | Iodixanol 320 (N=156) Ioversol 320 (N=143) |
No significant difference (Iodixanol 22%, Ioversol 24%, p=n.s.) |
| Ni et al. [21] | Patients with CRI | SCr ≥25% 24 h after administration | Iodixanol (N=120) Iopamidol (N=165) |
No significant difference (Iodixanol 11.7%, Iopamidol 19.4%, p=n.s.) |
| Hérnandez et al. [22] | Patients with diabetes | SCr ≥0.5 mg/dL and/or SCr ≥25% 72 h after administration | Iodixanol (N=118) Ioversol (N=132) |
Ioversol > Iodixanol (8.3% vs. 2.5%, p<0.05) |
| Solomon et al. [23] | Patients with CRI | SCr ≥0.5 mg/dL 48–72 h after administration | Iodixanol 320 (N=210) Iopamidol 370 (N=204) |
No significant difference (Iodixanol 7%, Iopamidol 4%, p=n.s.) |
| Nie et al. [24] | Patients with CRI | SCr ≥0.5 mg/dL and/or SCr ≥25% 1–2 days after administration | Iodixanol 320 (N=106) Iopromide 370 (N=102) |
Iopromide >Iodixanol (16.7% vs. 5.7%, p<0.01.) |
| Wessely et al. [25] | Patients with CRI | SCr ≥0.5 mg/dL and/or SCr ≥25% 1–2 days after administration | Iodixanol 320 (N=162) Iomeprol 350 (N=162) |
No significant difference (Iodixanol 22.2%, Iomeprol 27.7%, p=n.s.) |
| Mehran et al. [26] | Patients with CRI | SCr ≥0.5 mg/dL and/or SCr ≥25% 1–2 days after administration | Iodixanol 320 (N=72) Ioxaglate 320 (N=74) |
No significant difference (Iodixanol 15.9%, Ioxaglate 24.2%, p=n.s.) |
| Laskey et al. [27] | Patients with CRI and diabetes | SCr ≥0.5 mg/dL 24, 48 and 72 h after administration | Iodixanol 320 (N=215) Iopamidol 370 (N=203) |
No significant difference (Iodixanol 11%, Iopamidol 9%, p=n.s.) |
| Shin et al. [28] | Patients with CRI | SCr ≥0.5 mg/dL 24, 48 and 72 h after administration | Iodixanol 320 (N=215) Iopromide 300 (N=205) |
No significant difference (Iodixanol 10.7%, Iopromide 7.8%, p=n.s.) |
| Bolognese et al. [29] | Patients with CRI | SCr ≥25% 72 h after administration | Iodixanol 320 (N=236) Iopromide 370 (N=239) |
No significant difference (Iodixanol 13%, Iopromide 10%, p=n.s.) |
| Juergens et al. [30] | Patients with CRI | SCr ≥0.5 mg/dL and/or SCr ≥25% 48 h after administration | Iodixanol 320 (N=91) Iopromide 370 (N=100) |
No significant difference (Iodixanol 12%, Iopromide 15%, p=n.s.) |
| Chen et al. [31] | Patients with CRI | SCr ≥50% 72 h after administration | Iodixanol 320 (N=284) Iopromide 370 (N=278) |
No significant difference (Iodixanol 0.3%, Iopromide 0.4%, p=n.s.) |